[go: up one dir, main page]

CR20110553A - Terapia complementaria contra el cáncer - Google Patents

Terapia complementaria contra el cáncer

Info

Publication number
CR20110553A
CR20110553A CR20110553A CR20110553A CR20110553A CR 20110553 A CR20110553 A CR 20110553A CR 20110553 A CR20110553 A CR 20110553A CR 20110553 A CR20110553 A CR 20110553A CR 20110553 A CR20110553 A CR 20110553A
Authority
CR
Costa Rica
Prior art keywords
against cancer
therapy against
complementary therapy
complementary
compositions
Prior art date
Application number
CR20110553A
Other languages
English (en)
Inventor
Gwendolyn Fyfe
Eric Hedrick
Robert D Mass
Norman Wolmark
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of CR20110553A publication Critical patent/CR20110553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fertilizers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente solicitud, se revelan métodos y composiciones que comprenden anticuerpos anti-VEGF para el uso en la terapia complementaria del cáncer.
CR20110553A 2009-04-20 2011-10-19 Terapia complementaria contra el cáncer CR20110553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
CR20110553A true CR20110553A (es) 2012-01-23

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110553A CR20110553A (es) 2009-04-20 2011-10-19 Terapia complementaria contra el cáncer

Country Status (19)

Country Link
US (1) US20100266589A1 (es)
EP (1) EP2421558A1 (es)
JP (1) JP2012524083A (es)
KR (1) KR20120096401A (es)
CN (1) CN102458467A (es)
AR (1) AR076344A1 (es)
AU (1) AU2010239368A1 (es)
BR (1) BRPI1006438A2 (es)
CA (1) CA2759030A1 (es)
CL (1) CL2011002610A1 (es)
CO (1) CO6450651A2 (es)
CR (1) CR20110553A (es)
IL (1) IL215764A0 (es)
MA (1) MA33323B1 (es)
MX (1) MX2011010955A (es)
RU (1) RU2011147051A (es)
SG (1) SG175289A1 (es)
TW (1) TW201106969A (es)
WO (1) WO2010123891A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3357932A1 (en) * 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PL3072526T3 (pl) 2009-10-16 2019-04-30 Oncomed Pharm Inc Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych
JP5808054B2 (ja) 2009-12-25 2015-11-10 中外製薬株式会社 Ｎｏｇ樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
CA3022256C (en) 2010-06-03 2021-03-30 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SG196836A1 (en) 2010-10-06 2014-02-13 Pharmalogicals Res Pte Ltd Cancer stem cell population and method for production thereof
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
RS58201B1 (sr) 2011-09-23 2019-03-29 Oncomed Pharm Inc Vegf/dll4 vezujući agensi i njihova upotreba
JP6291254B2 (ja) * 2011-10-28 2018-03-14 中外製薬株式会社 癌幹細胞特異的分子
CA2874144C (en) * 2012-05-31 2023-12-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
BR112015002681A2 (pt) * 2012-08-07 2018-08-28 Genentech Inc método para tratar um paciente e kit
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
EP2914263A4 (en) 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
WO2014190311A2 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective mismatch repair and benefit from bevacizumab for colon cancer
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
CN106460067A (zh) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 诊断方法和用于治疗成胶质细胞瘤的组合物
CA2966042A1 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2017042318A1 (en) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Chemerin polypeptide for the treatment of cancer-induced cachexia
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
EP0973804B1 (en) * 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP2311875A1 (en) * 2003-05-30 2011-04-20 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
KR20140148491A (ko) * 2006-12-19 2014-12-31 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
TW200838875A (en) * 2007-02-01 2008-10-01 Genentech Inc Combination therapy with angiogenesis inhibitors
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
CO6450651A2 (es) 2012-05-31
TW201106969A (en) 2011-03-01
IL215764A0 (en) 2012-01-31
CN102458467A (zh) 2012-05-16
KR20120096401A (ko) 2012-08-30
BRPI1006438A2 (pt) 2016-09-27
CA2759030A1 (en) 2010-10-28
CL2011002610A1 (es) 2012-04-09
WO2010123891A1 (en) 2010-10-28
JP2012524083A (ja) 2012-10-11
MA33323B1 (fr) 2012-06-01
SG175289A1 (en) 2011-11-28
AU2010239368A1 (en) 2011-11-10
RU2011147051A (ru) 2013-05-27
EP2421558A1 (en) 2012-02-29
AR076344A1 (es) 2011-06-01
US20100266589A1 (en) 2010-10-21
MX2011010955A (es) 2012-04-02

Similar Documents

Publication Publication Date Title
CR20110553A (es) Terapia complementaria contra el cáncer
MX373334B (es) Composiciones y métodos.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
IN2012DN02046A (es)
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
EA201400178A1 (ru) Лечение рака молочной железы
EA201171367A1 (ru) Винилиндазолильные соединения
BR112013028422A2 (pt) ativadores de piruvato cinase para uso em terapia
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AR077237A1 (es) Polimeros colorantes
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
DK2252322T3 (da) Vaccinesammensætninger
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
MY161601A (en) Films and compositions comprising the same
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
EA201591709A1 (ru) 5-бром-индирубины
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos